Stifel Sees 134% Upside in Summit Therapeutics as Ivonescimab Eyes $200B Market
Stifel rates Summit Therapeutics a Buy. Its new cancer drug looks promising, and strong trial results could send the stock much higher.
/ 124 items
#XY Analyst Up/Down↓
Gilead’s $5B Tubulis Deal Validates ADC Space – Bullish for Sutro Biopharma
Leerink sees major tailwind for Sutro Biopharma and initiates coverage with $38 price target.
Bio-Rad Faces Headwinds as Citi Downgrades Shares to Neutral
Citi downgrades Bio-Rad to Neutral, citing weak chromatography growth and China market risks; price target cut to $300.
Tyra Biosciences Receives Buy Rating – Key 2026 Data Ahead
Tyra Biosciences’ dabogratinib shows promise: works well for bladder cancer & dwarfism with fewer side effects. Big 2026 trials ahead.
Wedbush Upgrades Arcus Biosciences Ahead of Key 2026 Clinical Data
Wedbush upgraded Arcus Biosciences with a new $41 price target and added the stock to its Best Ideas List ahead of major 2026 clinical updates for casdatifan in kidney cancer.
Oppenheimer Sees $1 Billion Potential in Passage Bio’s PBFT02 for FTD
Oppenheimer just started coverage on Passage Bio with an Outperform rating and $30 price target. They call the recent pullback a buying opportunity ahead of key PBFT02 data in H1 2026.